Psychiatry

Back to articles

Antidepressants plus NSAIDs: Increased risk of intracranial hemorrhage

August 25, 2015
  • Advising on this article:
  • M. Lynn Crismon

KEY POINT

The concurrent use of antidepressants and nonsteroidal anti-inflammatory drugs (NSAIDs) was linked to an early increased risk for intracranial hemorrhage, according to results of a retrospective cohort study published online in BMJ.

SOURCES

Shin JY et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. 2015;[Epub ahead of print]. 

Mercer SW et al. Risk of intracranial haemorrhage linked to co-treatment with antidepressants and NSAIDs. BMJ. 2015;[Epub ahead of print].

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.